TRANSLATIONAL ONCOLOGY PROGRAM

转化肿瘤学（TO）计划的使命是开发临床试验，促进基础科学家，转化科学家和临床医生之间的互动，以促进改善临床结果。在上一次审查期间，该计划被组织成以下三个专题领域，这些领域在特定疾病工作组中得到强调：（1）开发和开展早期临床试验，目标是将研究结果转化为合作组或III期环境;（2）促进将预测和预后生物标志物特征纳入临床试验;（3）开发与抗血管生成药物、信号通路和活性氧（ROS）相关的新的治疗方法。为了促进程序间和程序内的相互作用和翻译活动，最近针对黑素瘤、乳腺癌、GI癌、前列腺癌和宫颈癌/GYN癌建立了疾病特异性翻译工作组（TWG）。通过与其他项目（包括肿瘤成像（新辅助乳腺）和癌细胞生成和信号传导（CML，前列腺））的项目间合作，开发了与转化终点相关的临床试验。在过去的五年里，我们的计划一直专注于临床研究试验的应计费用，包括假设驱动的，制药商发起的试验（HDII），合作组和制药商赞助的试验。重点一直放在HDII试验，以利用UCI丰富的综合癌症中心资源，开发新的方法来治疗癌症。在过去六年中，HDII的应计人数从2002-2004年的60人急剧增加到2005-2007年的175人。2002-2003年，不包括化学预防试验的总体干预性临床试验累计数为142项，2004-2005年增加到218项，2005-2007年迄今为止为387项。特别重要的是，这种累计数的增长与翻译终点有关，这些终点导致了同行评审资金和高影响力期刊上的出版物数量增加。 TO计划有25名成员，代表八个部门和一所学校，并有2，024，203美元的直接癌症相关的同行评审资金，其中10个项目由NCI资助，直接总额为1，187，498美元。在2007年，委员会共出版了71份刊物，其中62份与癌症有关，当中44%与委员会之间有关，16%与委员会内部有关。

The Translational Oncology (TO) Program's mission is to develop clinical trials that promote interaction between basic scientists, translational scientists, and clinicians to facilitate improved clinical outcomes. During the last review period the Program was organized into the following three thematic areas that are emphasized in disease-specific working groups: (1) Develop and carry out early phase clinical trials with a goal to translate findings into the cooperative group or phase III setting; (2) Facilitate inclusion of predictive and prognostic biomarker profiles in clinical trials; (3) Develop novel therapeutic approaches related to antiangiogenesis agents, signaling pathways and reactive oxygen species (ROS). In order to promote interprogrammatic and intra-programmatic interactions and translational activities, disease specific translational working groups (TWGs) were recently established for melanoma, breast, Gl, prostate and cervical/GYN cancers. Clinical trials coupled to translational endpoints have been developed through inter-programmatic collaborations with other Programs, including Oncoimaging (Neoadjuvant breast), and Cacinogenesis and Signaling (CML, prostate). Over the past five years, our Program has focused on accrual to clinical research trials, including Hypothesis-driven, investigator-initiated trials (HDII), cooperative group, and pharmaceutical sponsored trials. Emphasis has been placed on HDII trials to exploit UCI's rich Comprehensive Cancer Center resources to develop novel approaches to cancer care. HDII accrual over the past six years has grown dramatically from 60 in 2002-2004 to 175 in 2005-2007. Overall interventional clinical trials accrual, excluding chemoprevention trials, was 142 in 2002-2003, increasing to 218 in 2004-2005, and 387 to date in 2005-2007, Of particular significance, this growth in accrual was linked to translational endpoints that led to peer reviewed funding and increased numbers of publications in high impact journals. The TO Program has 25 Members, representing eight Departments and one School, and has $2,024,203 in direct cancer-related peer-reviewed funding, 10 projects of which are funded by NCI for a direct total of $1,187,498. In 2007, Members published a total of 71 publications with 62 of those being cancer-related of which 44% were inter- and 16% were intra-related.